VST Bio

Executive Summary

VST Bio is a private biotechnology company headquartered in Cambridge, Massachusetts, founded in 2021. The company is pioneering first-in-class antibody therapeutics that target novel pathways regulating vascular permeability and inflammation. Its lead programs are focused on acute ischemic stroke, with potential extensions into myocardial infarction, sepsis, and other critical care diseases. VST Bio leverages its proprietary platform to address significant unmet needs in conditions where vascular leakage and inflammatory cascades drive pathology. As a preclinical-stage company with no disclosed funding rounds or pipeline details, VST Bio represents an early-stage investment opportunity in the antibody therapeutics space. The company's approach could differentiate it from competitors by targeting upstream regulators of vascular integrity, though clinical validation remains years away.

Upcoming Catalysts (preview)

• Q4 2026Preclinical Proof-of-Concept Data in Ischemic Stroke Models40% success
• H2 2026Series A Financing or Grant Announcement50% success
• Q1 2027IND-Enabling Studies Initiation30% success